British Patient Capital (BPC)
Edit

British Patient Capital (BPC)

https://www.britishpatientcapital.co.uk
Last activity: 22.10.2024
Active
Invests in categories: InvestmentTechnologyFinTechGrowthDataITHealthTechQuantumSoftwareFirm
Our mission is to enable long-term investment in innovative companies across the UK led by ambitious entrepreneurs.

The UK provides a fertile ground for innovation to thrive, but a lack of access to patient capital continues to hold back some UK companies from scaling up and fulfilling their commercial potential. British Patient Capital will enable greater availability of this type of long-term finance and will help build the UK’s innovation economy.

British Patient Capital will be developed as a separate subsidiary of the British Business Bank and builds on a successful 10-year heritage of investing £1bn into UK venture and growth capital.
News
69
Portfolio
28
Persons
1
Mentions
90
Location: United Kingdom, England, Sheffield
Employees: 11-50
Founded date: 2018
Investment Stage: Series A; Series B; Series C; Series E

Portfolio 28

DateNameWebsiteTotal RaisedLocation
12.09.2024Form3form3.tech$293.85M-
31.10.2023Northern G...northern-gritstone.com$624.42MGermany, S...
31.10.2023CyberSmartcybersmart.co.uk$34.13MUnited Kin...
31.10.2023Garrisongarrison.com$44.64MUnited Kin...
13.07.2023Tenpoint T...tenpointtx.com.com$70MBelgium, A...
13.07.2023Tenpoint T...tenpointtherapeutics.com$82.72M-
15.05.2023OMass Ther...omass.com$112.51MUnited Kin...
02.03.2023Quantum Mo...quantummotion.tech$61.06M-
27.01.2023Grey Wolf ...greywolftherapeutics.com$111.86MUnited Sta...
12.01.2023Perspectum...perspectum.com$126.97MUnited Kin...
Show more

Persons 1

DateFirst NameLast NameTitleLinkedIn
-AlexandraWoodmanVenture Ca...linkedin.c...

News 69

DateTitleDescription
07.12.2023British Patient Capital Invests £5.5m in Pragmatic Semiconductor06 December 2023: British Patient Capital has made a £5.5 million investment into Pragmatic Semiconductor, a Cambridge-based designer and manufacturer of semiconductors, as part of a £162m first close of its Series D funding round, with a s...
29.11.2023British Patient Capital announces £25m commitment to Oxx II29 November 2023: British Patient Capital announces today a £25m commitment to the second fund by Oxx, a specialist investor in European B2B SaaS companies at the scale-up stage.
27.11.2023British Patient Capital – Full Year Results for the period ending 31 March 202327 November 2023: Investing in tomorrow: British Patient Capital’s total fund and co-investment commitments reach £1.9bn.
08.11.2023British Patient Capital announces £20m commitment to Connect Ventures’ fourth fund05 September 2023
08.11.2023British Patient Capital Response to Nations and Regions Tracker 202312 October 2023: Today the British Business Bank published its Nations and Regions Tracker 2023.
13.07.2023British Patient Capital invests £10m in Tenpoint Therapeutics12 July 2023: British Patient Capital has invested £10m in Tenpoint Therapeutics, an engineered cell-based therapeutics and in vivo reprogramming company developing breakthrough regenerative treatments for ocular diseases, as part of a $70 ...
26.06.2023British Patient Capital Response to Small Business Equity Tracker 202315 June 2023: Today the British Business Bank published its Small Business Equity Tracker 2023.
15.05.2023British Patient Capital Invests £10m in next generation drug development company OMass Therapeutics15 May 2023: British Patient Capital has made a £10 million investment into OMass Therapeutics, a platform therapeutic company that discovers and develops novel small molecule medicines in areas of high, unmet clinical need, to help advance...
26.04.2023Catherine Lewis La Torre to step down as CEO of British Patient Capital in December 2023 after seven years’ serviceCatherine Lewis La Torre has announced that she will be standing down from the role of CEO of British Patient Capital, a commercial subsidiary of the British Business Bank, in December 2023 after seven years’ service with the Bank.
24.04.2023British Patient Capital announces $26.7m commitment to Kindred Capital’s third fund20 April 2022: British Patient Capital announces today a $26.7m commitment to Kindred Capital’s (“Kindred”) third fund as Kindred announces its close today at $130m.
Show more

Mentions in press and media 90

DateTitleDescription
22.10.2024Nuclera: Biotech Company Raises $75 Million For Accelerating Protein ExpressionNuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, announced it had completed a $75 million financing round (circa £57 million). The funding round was led by El...
17.10.2024Nuclera's $75 Million Leap: A New Era for Protein DiscoveryIn the world of biotechnology, speed is everything. Nuclera, a Cambridge-based biotech company, has just secured a $75 million Series C funding round. This significant investment is a game-changer, pushing the boundaries of protein discover...
16.10.2024Nuclera raises $75M Series C for eProtein discovery systemBiotech Nuclera has raised a $75 million Series C financing round. This brings the company’s funding to over $140 million. The company is accelerating protein expression and purification workflows through its benchtop protein system, eProte...
20.09.2024Form3: Cloud-Native Account-To-Account Platform Company Closes $60 Million (Series C Extension)Form3, a cloud-native account-to-account platform, announced a new investor: British Patient Capital. Along with existing strategic and financial investors, including Visa, Form3 has now raised a total of $60 million in C-series extension f...
12.09.2024British Patient Capital invests £10M in Form3British Patient Capital has made a £10m investment into Form3, a leading British payment technology company. The investment is part of Form3’s Series C extension and will see British Patient Capital join existing investors including Visa an...
10.09.2024Epsilogen Secures £12.5 Million to Propel Cancer Treatment InnovationsEpsilogen, a pioneering force in the realm of immunoglobulin E (IgE) antibodies, has successfully raised £12.5 million in a Series B funding round. This brings the total Series B financing to an impressive £43.25 million. The funds will be ...
10.09.2024Form3 Completes $60M Series C ExtensionForm3, a London, UK-based provider of a cloud-native account-to-account platform, raised $60M in Series C extension funding. Backers included British Patient Capital and Visa. The company intends to use the funds to develop new products and...
09.09.2024Epsilogen: Immunoglobulin Development Company Raises £12.5 Million (Series B)Epsilogen – a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer – announced today the completion of a £12.5 million Series B expansion financing, bringing the Series B total to £43.25 million. The funding will a...
30.07.2024Kennet's Bold Move: €266 Million Fund for B2B SaaS GrowthIn a world where financial landscapes shift like sand, Kennet Partners has anchored itself firmly with the launch of its largest fund to date. The transatlantic growth equity investor has successfully raised €266 million for Kennet VI, a fu...
29.07.2024Kennet closes €266M fund for B2B SaaSTransatlantic growth equity investor Kennet has raised €266M for its largest fund to date, Kennet VI. Kennet has already begun to deploy this capital into B2B SaaS companies across Europe, including Screendragon in Ireland and the UK and Fl...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In